<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00019734</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000067075</org_study_id>
    <secondary_id>NCI-99-C-0095</secondary_id>
    <secondary_id>NCI-T99-0025</secondary_id>
    <nct_id>NCT00019734</nct_id>
    <nct_alias>NCT00001811</nct_alias>
  </id_info>
  <brief_title>Vaccine Therapy in Treating Patients With Metastatic Melanoma</brief_title>
  <official_title>Immunization of Patients With Metastatic Melanoma Using Recombinant Fowlpox and Vaccinia Viruses Encoding the Tyrosinase Antigen</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Vaccines may make the body build an immune response to kill tumor cells.&#xD;
      Interleukin-2 may stimulate a person's white blood cells to kill tumor cells.&#xD;
&#xD;
      PURPOSE: Randomized phase II trial to study the effectiveness of vaccine therapy with and&#xD;
      without interleukin-2 in treating patients who have metastatic melanoma that has not&#xD;
      responded to previous treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine efficacy of recombinant fowlpox and vaccinia viruses encoding tyrosinase&#xD;
           antigen, administered with or without low-dose interleukin-2 (IL-2), in terms of&#xD;
           response, in patients with metastatic melanoma.&#xD;
&#xD;
        -  Compare the response rate in patients to this vaccination administered with high-dose&#xD;
           IL-2 to that in similar patients on previous trials treated with high-dose IL-2 alone.&#xD;
&#xD;
        -  Determine the immunological response in patients treated with this regimen.&#xD;
&#xD;
      OUTLINE: This is a randomized study. Patients are randomized to one of three treatment arms.&#xD;
&#xD;
        -  Arm I: Patients receive recombinant fowlpox vaccine IM on day 1 followed 4 weeks later&#xD;
           by recombinant vaccinia vaccine IM. Treatment repeats for a minimum of 4 vaccinations.&#xD;
&#xD;
        -  Arm II: Patients receive vaccinations as in arm I plus low-dose interleukin-2 (IL-2)&#xD;
           subcutaneously daily on days 2-13 after each vaccination.&#xD;
&#xD;
        -  Arm III: Patients receive vaccinations as in arm I plus high-dose IL-2 IV over 15&#xD;
           minutes every 8 hours on days 2-5 after each vaccination.&#xD;
&#xD;
      Patients with stable disease or a minor, mixed, or partial response after four immunizations&#xD;
      (1 course) may receive a second course of the same regimen beginning 4-6 weeks after the&#xD;
      first course. After the second course, patients with tumor regression may continue to receive&#xD;
      treatment in the absence of unacceptable toxicity until best response is achieved.&#xD;
&#xD;
      Patients are followed at 4-6 weeks.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 73 patients (13-20 for arm I, 13-20 for arm II, and 19-33 for&#xD;
      arm III) will be accrued for this study within 2 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 1999</start_date>
  <completion_date type="Actual">May 2003</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Melanoma (Skin)</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>aldesleukin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>fowlpox virus vaccine vector</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>vaccinia-tyrosinase vaccine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed metastatic melanoma that has failed standard treatment&#xD;
&#xD;
          -  No ocular or mucosal melanoma as primary site&#xD;
&#xD;
          -  Measurable disease&#xD;
&#xD;
          -  No existing brain metastases&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  16 and over&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  ECOG 0 or 1&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  More than 3 months&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  WBC at least 3,000/mm3&#xD;
&#xD;
          -  Platelet count at least 90,000/mm3&#xD;
&#xD;
          -  No coagulation disorder&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin no greater than 1.6 mg/dL&#xD;
&#xD;
          -  AST/ALT less than 3 times normal&#xD;
&#xD;
          -  Hepatitis B surface antigen negative&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine no greater than 1.6 mg/dL&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  No major cardiovascular illness&#xD;
&#xD;
        Pulmonary:&#xD;
&#xD;
          -  No major respiratory illness&#xD;
&#xD;
        Immunologic:&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  No autoimmune disease&#xD;
&#xD;
          -  No primary or secondary immunodeficiency&#xD;
&#xD;
          -  No allergy to eggs&#xD;
&#xD;
          -  No history of allergy or untoward reaction to prior smallpox vaccination&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  Must be able to avoid close contact with children under 5 years, pregnant women,&#xD;
             people with active or a past history of eczema or other eczematoid skin disorders, and&#xD;
             immunosuppressed people for at least 2 weeks after each vaccinia virus vaccination&#xD;
&#xD;
          -  No active systemic infections&#xD;
&#xD;
          -  No active atopic dermatitis or active or past history of eczema&#xD;
&#xD;
          -  No concurrent active extensive psoriasis, severe acneiform rash, impetigo, varicella&#xD;
             zoster, burns, or other traumatic or pruritic skin conditions or open wounds&#xD;
&#xD;
          -  Surgical scars must be healed&#xD;
&#xD;
          -  Healed surgical stomas (e.g., colostomy) allowed&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  No prior recombinant vaccinia or fowlpox vaccines for melanoma&#xD;
&#xD;
          -  At least 3 weeks since prior systemic biologic therapy for melanoma&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  At least 3 weeks since prior systemic chemotherapy for melanoma&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  At least 3 weeks since prior systemic endocrine therapy for melanoma&#xD;
&#xD;
          -  No concurrent steroid therapy&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  At least 3 weeks since prior systemic radiotherapy for melanoma&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  Prior surgery allowed&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Suzanne L. Topalian, MD</last_name>
    <role>Study Chair</role>
    <affiliation>NCI - Surgery Branch</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Surgery Branch</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2007</verification_date>
  <study_first_submitted>July 11, 2001</study_first_submitted>
  <study_first_submitted_qc>May 27, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 28, 2003</study_first_posted>
  <last_update_submitted>June 19, 2013</last_update_submitted>
  <last_update_submitted_qc>June 19, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 20, 2013</last_update_posted>
  <keyword>stage IV melanoma</keyword>
  <keyword>recurrent melanoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aldesleukin</mesh_term>
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

